Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Industri |
| Industri | Industriprodukter |
An extraordinary general meeting in ChromoGenics AB (publ) was held on 18 December 2019 at the company's premises on Söderforsgatan 1 in Uppsala whereby the shareholders primarily resolved on the following matters.
Resolution on adoption of new articles of association
The extraordinary general meeting resolved to adopt new articles of association regarding the limits for the share capital (§ 4) and the number of shares (§ 5) in accordance with the following.
Previous wording
§ 4 The company's share capital shall be not less than SEK 35,000,000 and not more than SEK 140,000,000.
§ 5 The number of shares in the company shall be not less than 175,000,000 and not more than 700,000,000.
New wording
§ 4 The company's share capital shall be not less than SEK 80,000,000 and not more than SEK 320,000,000.
§ 5 The number of shares in the company shall be not less than 400,000,000 and not more than 1,600,000,000.
The managing director, or any person appointed by the board of directors, is authorised to make such smaller adjustments to the resolution that may be necessary in connection with registration of the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.
Resolution on authorisation to the board of directors to resolve on new issues of shares
The extraordinary general meeting of shareholders resolved to authorise the board of directors to, on one or several occasions for the period up to the next annual general meeting, resolve on an increase of the company's share capital by an issue of new shares. The board of directors is authorised to resolve on an issue of shares with pre-emption rights for existing shareholders and on an issue in kind and/or by way of set off. The authorisation may be used for issues of shares within the limits of the company's articles of association.
An issue in accordance with the authorisation shall be on market conditions. The board of directors is authorised to decide on the terms and conditions regarding issues under the authorisation. The reason that the board of directors shall be authorised to resolve on an issue in kind and/or by way of set-off is that the company shall be able to carry out new issues of shares to raise capital to the company.
The managing director, or any person appointed by the board of directors, is authorised to make such smaller adjustments to this resolution that may be necessary in connection with registration of the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.
The resolutions at the extraordinary general meeting were adopted unanimously.
Uppsala on 18 December 2019
ChromoGenics AB (publ)
The board of directors